Pulmonary Drug Delivery Market will reach USD 72.88 billion by 2030
The research studies of Global Pulmonary Drug Delivery Market report helps to evaluate several important parameters that can be mentioned as investment in a rising market, success of a new product, and expansion of market share. By accomplishing an inspiration from the marketing strategies of rivals, businesses can set up inventive ideas and striking sales targets which in turn make them achieve competitive advantage over its competitors. This analysis gives an examination of various segments that are relied upon to witness the quickest development amid the estimate forecast frame. Global Pulmonary Drug Delivery Market document performs market share assessments for the regional and country-level segments.
The dependable Global Pulmonary Drug Delivery Market report explains market analysis based on regional, local as well as global level. It analyses the key factors which leads to market growth as well as restraints of the market growth. Analytical study of this market report helps in mapping growth strategies to increase sales and build brand image in the market. This business report deeply attempts to determine the impact of buyers, substitutes, new entrants, competitors, and suppliers on the market. Global Pulmonary Drug Delivery Market report comprises of a detailed analysis of the market with key players, applications, types, and regions.
The main objective of the drug delivery method, pulmonary drug delivery, is to place inhaled pharmacological agents in the lower airways using tools that facilitate oral inhalation of drug formulations. They are widely used in various end-user industries, including healthcare facilities like hospitals, clinics, and nursing homes. Various equipment is used for respiratory delivery, such as nebulizers, metered-dose inhalers, and dry powder inhalers. The lungs are used to deliver inhaled beta-agonists, corticosteroids, and anticholinergic drugs to treat asthma and chronic obstructive pulmonary disease (COPD). The pulmonary administration method offers several benefits. The medication is applied directly to the disease site to treat respiratory infections.
Download PDF Sample Report (Including Graphs, Charts, and List of Figures) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pulmonary-drug-delivery-market&Shri
Data Bridge Market Research analyses that the pulmonary drug delivery market, valued at USD 47.85 billion in 2022, will reach USD 72.88 billion by 2030, growing at a CAGR of 5.4% during the forecast period of 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
“Increasing prevalence of respiratory diseases surge market demand”
The increasing prevalence of respiratory diseases, including asthma, COPD, and cystic fibrosis, is a significant driver for the pulmonary drug delivery market. These conditions require effective treatments directly targeting the lungs to provide quick relief or long-term management. Pulmonary drug delivery offers a direct and efficient method of delivering medications to the respiratory system, meeting the demand for optimized therapies and contributing to market growth.
What restraints the growth of the pulmonary drug delivery market?
“Limited drug compatibility can impede the market growth”
The limited drug compatibility is a restraint in the pulmonary drug delivery market, as not all drugs can be effectively delivered via inhalation. Factors like stability, solubility, and suitability for inhalation impact drug formulation for pulmonary delivery. This limitation narrows down the range of drugs that can be administered through pulmonary routes, limiting market potential. Overcoming these challenges requires innovative formulation technologies and careful consideration of drug properties for successful pulmonary delivery.
Pulmonary Drug Delivery Market Scope and Segmentation
| REPORT METRIC | DETAILS |
| Forecast Period | 2023 to 2030 |
| Base Year | 2022 |
| Historic Years | 2021 (Customizable to 2015 – 2020) |
| Quantitative Units | Revenue in USD Billion, Volumes in Units, Pricing in USD |
Market Definition
Directing the drug to the intended site is referred to as “targeted drug delivery.” A targeted drug delivery system called pulmonary drug delivery requires the drug moiety toward the lower respiratory tract. A device used to administer medications to the body via the pulmonary route is called a pulmonary drug delivery system. The inhalation route offers a superior alternative to oral administration for treating asthma and chronic obstructive pulmonary disease. Instantaneous action from pulmonary drug delivery relieves acute bronchitis and asthmatic attacks. For pulmonary drug delivery, aerosols are specially made-devices.
Some of the major players operating in the pulmonary drug delivery market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- MannKind Corporation (U.S.)
- OMRON Healthcare, Inc. (Japan)
- Mylan N.V (U.S.)
- 3M (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- Merck & Co., Inc., (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sunovion Pharmaceuticals Inc. (U.S.)
- PARI GmbH (Germany)
- Jabil Inc. (U.S.)
- AstraZeneca (U.K.)
- Boehringer Ingelheim International GmbH. (Germany)
- GSK plc. (U.K.)
- Novartis AG (Switzerland)
- Aerogen Pharma (Ireland)
- Briggs Healthcare (U.S.)
- HAAG-STREIT GROUP (Switzerland)
- Janssen Global Services, LLC (U.S.)
- AptarGroup, Inc. (U.S.)
To Gain More Insights into the Market Analysis, Browse the Summary of the Research Report@ https://www.databridgemarketresearch.com/reports/global-pulmonary-drug-delivery-market?Shri
Drivers
- Rising prevalence of severe respiratory surges the demand
The rising prevalence of severe respiratory diseases like cystic fibrosis and chronic obstructive pulmonary disease is driving the growth of the pulmonary drug delivery market. Additionally, the growing demand for minimally invasive and effective treatments and the rising trend of pulmonary drug delivery due to features of a large porous area, thin absorbent mucosal membrane, and efficient blood supply will boost the market growth. Additionally, the rising smoking prevalence can impact respiratory, further accelerating the market’s overall growth.
- The prevalence of pulmonary diseases drives the market
An increase in air pollution in the prevalence of pulmonary diseases such as asthma and chronic obstructive pulmonary disease, has showcase growing number of hospitals and diagnostic facilities, a surge in funding from private and public organizations for the treatment of pulmonary diseases, and an increase in public awareness of pulmonary health are the main factors driving the global market for pulmonary drug delivery systems. The World Health Organization reports that 9 out of 10 people breathe air that contains high levels of pollutants, and estimates indicate that in 2018, ambient (outdoor) and household air pollution will be responsible for an alarming 7 million annual deaths.
Recent Developments
- In 2022, Subintro’s acquisition by RIGImmune gave it access to cutting-edge topical delivery systems. With this agreement, the biotech is better positioned to advance the creation of cutting-edge RNA therapies and vaccine adjuvants for local mucosal delivery.
- In 2022, Orbital Dry Powder Inhaler (DPI) worldwide license was acquired by Aptar Pharma. This acquisition will enable Aptar Pharma to meet the rising demand for easy and secure high-dose lung treatment administration.
- In 2020, The U.S. Food and Drug Administration (FDA) received a New Drug Application (NDA) for UPTRAVI (selexipag) as an intravenous (IV) injection to treat pulmonary arterial hypertension from Johnson & Johnson’s Janssen Pharmaceutical Companies.
- In 2020, The Japanese Ministry of Health, Labour, and Welfare (MHLW) simultaneously approved new treatment options for Japanese patients, according to news released by Novartis Pharma K.K. (“Novartis Pharma”). For advanced and recurrent untreatable non-small cell lung cancer (NSCLC) with MET exon 14 skipping (METex14) mutation, TabrectaTM (capmatinib, formerly INC280) is an oral MET inhibitor.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the this research report
- Product Development/Innovation: Detailed insights on upcoming technologies, R&D activities, and product launches in the market
- Competitive Assessment: In-depth assessment of the market strategies, and geographic and business segments of the leading players in the market
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies
Top Key Topics Covered:
- Strategic Imperatives
- Factors Creating Pressure on Growth
- The Strategic Imperative
- Growth Opportunities Fuel the Growth Pipeline Engine
- Research Methodology
- Scope and Segmentation
- Research Context and Scope of Analysis
- Segmentation
- Other Techniques for This Research Report Management
- Growth Opportunity Analysis
- Growth Drivers
- Growth Restraints
- Introduction
- The Impact of the COVID-19 Pandemic and Post
- Future Growth
- Innovation Ecosystem
Continued…
Pulmonary Drug Delivery Market Scope
Formulations
- Type
- Suspension aerosol
- Solution Aerosal
- Dry power formulation
- Device type
- Dry Powder Inhalers
- Single-Dose Inhalers
- Multi-Dose Inhaler
- Metered Dose Inhalers
- Manually-Actuated Pressurized Inhaler
- Breath-Actuated Pressurized Inhaler
- Nebulizers
- Jet Nebulizers
- Soft Mist Nebulizers
- Ultra Wave Nebulizers
- Mesh
- Vibrating
- Static
- Pneumatic
- Vented
- Breath Actuated
- Accessories
Canister Type
- Plain Canister
- Coated Canister
Application
- Chronic Obstructive Pulmonary Disease (COPD)
- Asthma
- Cystic Fibrosis
- Allergic Rhinitis
- Other
End-User
- Hospitals and Clinics
- Home Care Settings
Browse Detailed Summary of Research Report with TOC: https://www.databridgemarketresearch.com/toc/?dbmr=global-pulmonary-drug-delivery-market&Shri
Some of the Most Important Questions Scrutinized in the Business Intelligence Report:
- What are the key growth parameters for this global market during the forecast period?
- Which key players are expected to hold the largest market share over the forecast period?
- Who are the leading vendors and manufacturers in this market?
- What are the key strategies adopted by leading players in the market for business development and geographical expansion?
- Which end-use industries can trigger high demand in the market over the forecast period?
- What are the key segments in this market?
- Which regional player will have anticipated leading the global market in terms of size?
- What is the impact of the novel coronavirus pandemic?
- Which obstacles must new players overcome in order to occupy a major position?
Top DBMR Healthcare Reports:
https://www.databridgemarketresearch.com/reports/global-cardasil-treatment-market?Shri
https://www.databridgemarketresearch.com/reports/global-aestheticcosmetic-lasers-market?Shri
https://www.databridgemarketresearch.com/reports/global-yeast-infection-market?Shri
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Contact Us:-
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- corporatesales@databridgemarketresearch.com
